

Page 1 of 8 Attorney Docket No.: 24492-011 NATL

Please type a plus sign (+) in this box	

PTO/SB (12-97) Approved for use through 9/30/00, OMB 0651-0031

		Under the Paper	work R	eduction Act	of 1995	, no pe	Patent and Trademark Patent and Trademark risons are required to respond to a collection of informati	office: U.S. DE on unless it displa	PARTMENT (OF COMMERCE		
Modified	Modified Form 1449/PTO						Application Number	10/532,2	295			
Modified	Woodled Form 1448/FTO						Filing Date	February 17, 2006				
	INFORMATION DISCLOSURE						First Named Inventor	Brand				
		EMENT BY AP					Group Art Unit	1647				
							Examiner Name	Elly Ger	ald Stoica	1		
	(use	as many sheets as r	neces	sary)			Attorney Docket Number		92-011 NATL			
			-		_	J.S.	PATENT DOCUMENTS					
Exam Initials	Cite No.	U.S. Patent Document No.	Iss	ue Date	Nan	ne o	f Patentee(s) or Applicant(s)	Class	Sub Class	Fillng Date If Appropriate		
	*A12	3,487,139	12/	/30/69	Moj	onni	er et al.	264	132			
	*A13	4,289,817	09/	/15/81	Val	yi		428	35			
	*A14	4,421,712	12/	/20/83	Wir	nstea	ıd	264	551			
	*A15	5,766,525	06	/16/98	And	derse	en et al.	264	40.1			
	*A16	5.885.956	03	/23/99	Nar	di et	al.	514	2			
	*A17	6,288,301 B1	-	/11/01			al.	800	18			
	*A18	6,358,924 B1		/19/02	-	fmai		514	12			
	*A19	6,558,952 B1		/06/03		ikh e		435	384	<u> </u>		
	*A20	6,899,883 B2		/31/05	Du	_	rt di.	424	198.1	-		
	*A21			/24/06	H	_		424	198.1			
	*A22	6,989,148 B2	-		Dup	_						
	*A23	6,992,060 B2	-	/31/06	Bra			514	2			
	AZS	7,037,504 B2	05	/02/06		gil e		424	198.1			
Exam Initials	Cite No.	U.S. Publishe Application No	d	Publishe Date			IED APPLICATION DOCUMENTS ne of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate		
	*A24	2002/0081285	\neg	06/27/02	2	Par	ikh et al.	424	93.21			
	*A25	2002/0119146	A1	08/29/02	2	Du	pre	424	139.1			
	*A26	2002/0182728	A1	12/05/02	2	Rai	miya et al.	435	366			
	*A27	2003/0032183	A1	02/13/03		She	eridan	435	370			
	*A28	2004/0023885	A1	02/05/04	<u>. </u>	Bra	ind et al.	514	12			
	*A29	2004/0037818		02/26/04			ind et al.	424	93.21			
	*A30	2004/0209801	-	10/21/04	\rightarrow		ind et al.	514	12			
	*A31	2004/0209816	-	10/21/04	-		rikh et al.	514	12			
	*A32	2004/0229810		11/18/04	_	Crt		514	14			
	*A34	2004/0266682		12/30/04	_	Cru		514	11	-		
	*A35	2006/0183674		08/17/06	_		and et al.	514	12			
	1	2000/0189520	^1	00/24/00		Dis	iliu et al.	314	112			

Page 2 of 8 Attorney Docket No.: 24492-011 NATL

	*A36	2006	5/0234373 A1	10/19/06	3	Rabinovitch et al.	435	325		
	*A37	2006	5/0234932 A1	10/19/06	3	Brand	514	12		
					FC	REIGN PATENT DOCUMENTS				
Exam initials	Cite No.	Foreig	n Patent Docu Number	ment	Nai	ne of Patentee(s) or Applicant(s)	Date of Publica	tion	Trans Yes	lation No
	B5	EP	0 507 555 A1			ERICAN HOME PRODUCTS RPORATION	10/07/9	2		
	В6	CA	2 494 134		WA	RATAH PHARMACEUTICALS, INC.	12/04/0	3		
	B7	CA	2 486 584		WA	RATAH PHARMACEUTICALS, INC.	12/18/0	3		
	B8	wo	95/19785			SEARCH TRIANGLE ARMACEUTICALS LTD.	07/27/9	5		
	В9	wo	00/044400			P PHARMA INC.; THE GENERAL SPITAL CORPORATION	08/03/0	0		
	B10	wo	02/055152 A	2	WA	ARATAH PHARMACEUTICALS, INC.	07/18/0	2		
	B11	wo	03/040310 A	2	WA	RATAH PHARMACEUTICALS, INC.	05/15/0	3		
	B12	wo	03/100024 A	2		RATAH PHARMACEUTICALS, INC.; IIVERSITY OF ALBERTA	12/04/0	3		
	B13	wo	03/103701 A	1	W	ARATAH PHARMACEUTICALS, INC.	12/18/0	3		
	B14	wo	2004/037195	A2	WA	ARATAH PHARMACEUTICALS, INC.	05/06/0	4		
	B15	wo	2004/045640) A1	W	ARATAH PHARMACEUTICALS, INC.	06/03/0	4	1	
	B16	wo	2004/096853	3 A1	W	ARATAH PHARMACEUTICALS, INC.	11/11/0	4		
	B17	wo	2004/105780	A2	W/	ARATAH PHARMACEUTICALS, INC.	12/0904	•		
	B18	wo	2005/072045	A2	W	ARATAH PHARMACEUTICALS, INC.	08//11/0	05		
	B19	wo	2006/002532	2 A1	w	ARATAH PHARMACEUTICALS, INC.	01/12/0	6	1	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C15	Adams et al., "Insulin-like growth factor-I promotes successful fetal pancreas transplantation in the intramuscular site", Surgery, 116:751-757 (1994)
	C16	Andrews et al., "Isolation and structures of Glucagon and Glucagon-like peptide from catfish pancreas", J. Biol. Chem., 260:3910-3914 (1985)
	C17	Baggio et al., "Sustained expression of exendin-4 does not perturb glucose homeostais, β-cell mass, or food intake in metallothionein-preproexendin transgenic mice", <i>J. Biol. Chem.</i> , 275:34472-34477 (2000)
	C18	Berendsen, "A glimpse of the holy grail?", Science, 282:642-643 (1998)
	C19	Brelje et al., "The physiological roles of prolactin, growth hormone and placental lactogen in the regulation of islet \(\begin{align*} exel proliferation", \textit{Pancreatic Growth and Regeneration, Ed. N. Sarvetnick, Ch. 1, pss. 1-30 (1997) \end{align*}
	C20	Carpenter et al., in Peptide Growth Factors, Chapter 4, "The Epidermal Growth Factor Family", eds. Sporn and Roberts, Springer Verlag, pgs. 69-171 (1990)
	C21	Chedid et al., "Regulation of Keratinocyte Growth Factor Gene Expression by Interleukin 1", <i>J Biol. Chem.</i> , 269(14):10753-10757 (1994)
	C22	Cunningham et al., "Receptor and antibody Epitopes in human growth hormone identified by homolog-scanning mutagenesis", Science, 243:1330-1336 (1989)
	C23	Cunningham, et al., "High-resolution epitope mapping of hGH-receptor interactions by alanine- scanning mutagenesis", Science, 244:1081-1085 (1989)

Page 3 of 8 Attorney Docket No.: 24492-011 NATL

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Exam initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C24	D'Alessio, et al., "Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal", J. Clin. Invest., 93:2263-2266 (1994).
	C25	Dockray et al., "Immunochemical Characterization of Gastrin in Pancreatic Islets of Normal and Genetically Obese Mice", J. Endocrinol., 72: pp 143-151 (1977)
	C26	Dupre, et al., "Insulinotropic Effect of Glucagon-Like Peptide I (7-36) Amide in C-Peptide-Positive Type I Diabetes Mellitus," Abstract 221, Page B38, Clin. Invest. Med. (1994)
	C27	Durrant et al, "Co-stimulation of Gastrointestinal Tumour Cell Growth by Gastrin, Transforming Growth Factor α and Insulin Like Growth Factor-1", Br. J. Cancer, 63:67-70 (1991)
	C28	Edwards et al., "Exendin-4 Reduces Fasting and Postprandial Glucose and Decreases Energy Intake in Healthy Volunteers", Am. J. Physiol. Endocrinol. Metab. 281:E155-E161 (2001)
	C29	Egan et al., "Glucagon-like Peptide-1 (7-36) Amide (GLP-1) Enhances Insulin-Stimulated Glucose Metabolism in 3T3-L1 Adipocytes: One of Several Potential Extrapancreatic Sites of GLP-1 Action", Endocrinol., 135(5):2070-2075 (1994)
	C30	Fehmann et al., "Insulinotropic Hormone Glucagon-like Peptide-1(7-37) Stimulation of Proinsulin Gene Expression and Proinsulin Biosynthesis in Insulinoma Beta TC-1 Cells", Endocrinol., 130(1):159-66 (1992)
	C31	Ghiglione et al., "How Glucagon-Like is Glucagon-Like peptide?", Diabetologia, 27:599-600 (1984)
	C32	Gil et al., "Polymeric Biomaterials as drug delivery systems", Boletim de Biotecnologia, 72:13-19 (2002)
	C33	Goeddel et al., "Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone", Nature, 281:544-548 (1979)
	C34	Goke et al., "Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-Amide an Antagonist at the Glucagon-Like Peptide 1-(7-36)-Amide Receptor of Insulin-Secreting Beta-Cells", J. Biol. Chem., 2681 9(56) 19(55) (1993)
	C35	Gray et al., "Periplasmic production of correctlyu processed human growth hormone in Escherichia coli: natural and bacterial signal sequences are interchangeable", Gene, 39:247-254 (1985)
	C36	Gromada et al., "Cellular Regulation of Islet Hormone Secretion by the Incretin Hormone Glucagon- like Peptide 1", Eur. J. Physiol., 435:583-94 (1998)
	C37	Gromada et al., "Desensitization of Glucagon-like Peptide 1 Receptors in Insulin-secreting .beta.TC3 Cells: Role of PKA-independent Mechanisms", Brit. J. Pharmacol., 118:769-775 (1996)
	C38	Gromada et al., "Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic .betaCells by Both Proximal and Distal Regulatory Steps in Stimulus-Secretion Coupling", <i>Diabetes</i> , 47:57-65 (1998)
	C39	Gutniak et al., "Glucagon-Like Insulinotropic Peptide 1 (7-36)—New Approach to Treating Diabetes?," Diabetologia, (Published from the 26.sup.th Annual Meeting of the European Association for the Study of Diabetes). Abstract 246, 33(Supp.).A73 (1990)
	C40	Gutniak et al, "Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus", N. Eng. J. Med., 326(20):1316-1322 (1992)
	C41	Hargrove et al, "Comparison of the Glucose Dependency of Glucagon-Like Peptide-1(7-37) and Glyburide In Vitro and In Vivo", Metabolism, 45(3):404-409 (1996)
	C42	Hargrove et al., "Glucose-Dependent Action of Glucagon-Like Peptide-1(7-37) In Vivo During Short- or Long-Term Administration," <i>Metabolism</i> , 44(9):1231-1237 (1995)
	C43	Hendrick et al., "Glucagon-like Peptide 1 (7-37) Blunts Postprandial Glycaemic Excursion in Rats with Mild Diabetes," Diabetologia, Abstract 212, 32(7):496A (1989)

Hendrick et al., "Glucagon-like Peptide-I-(7-37) Suppress Hyperglycemia in Rats", Metabolism, 42(1):1-6 (1993)
Hollande et al., "In Vitro Secretion of Gastrin, Insulin, and Glucagon in Tissue Cultures of Pancreas From a Child with Neonatal Intractable Hypoglycemia", Gastroenterology, 71:255-262 (1976)
Holst, J.J., "Glucagon Peptide 1: A Newly Discovered Gastrointestinal Hormone," Gastroenterology, 107(6):1848-1855 (1994)
Holstad et al., "Prolactin Protects Against Diabetes Induced by Multiple Low Doses of Streptozotocin in Mice", J. Endocrinol., 163:229-234 (1999)
Hui et al., "Glucagon-like peptide 1 induces differentiation of islet duodenalhomeobox-1-positive pancreatic ductal cells into insulin-secreting cells", <i>Diabetes</i> , 50:785-796 (2001)
Hvidberg et al., "Effect of Glucagon-like Peptide-1 (proglucagon78-107amide) on Hepatic Glucose Production in Healthy Man", Metabolism, 43(1):104-108 (1994)
Imura H., "A Novel Antidiabetic Drug, TroglitazoneReason for Hope and Concern", N. Engl. J. Med., 338:908-909 (1998)
Iritani et al., "Oral Triacylglycerols Regulate Plasma Glucagon-Like Peptide-1(7-36) and Insulin Levels in Normal and Especially in Obese Rats", J. Nutr., 129:46-50 (1999)
Johnson et al., "Erythropoietin mimetic peptides and the future", Nephrol. Dial Tranpl., 15:1274-1277 (2000)
Kaushansky, K., "Hematopoietic growth factor mimetics", Ann. NY Acad. Sci., 938:131-138 (2001)
Knudsen et al., "Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration", J. Med. Chem., 43(9):1664-1669 (2000)
Krakowski et al., "Pancreatic Expression of Keratinocyte Growth Factor Leads to Differentiation of Islet Hepatocytes and Proliferation of Duct Cells", Am. J. Pathol., 154:683-691 (1999)
Krakowski et al., "Transgenic Expression of Epidermal Growth Factor and Keratinocyte Growth Factor in Beta-Cells Results in Substantial Morphological Changes", J. Endocrinol., 162:167-175 (1999)
Kreymann et al., "Glucagon-like peptide-1 7-36: A physiological incretin in man," Lancet, 2:1300- 1304 (1987)
Kreymann et al., "Glucagon-like Peptide-1 7-36 Amide, A New Brain-Gut Hormone and Its Effect of Pancreatic Endocrine Function in Man," Biomed. Res. 9(Supp. 3):207-211 (1988)
Kumar, M., "Nano and microparticles as controlled drug delivery devices", J. Pharm. Pharmaceut. Sci., 3:234-258 (2002)
Kumar et al., "Biodegradable block copolymers", Adv. Drug Deliv. Rev., 53:23-44 (2001)
Larsen et al., "Glucagons-Like Peptide-1 Infusion Must Be Maintained For 24 H/Day To Obtain Acceptable Glycemia In Type 2 Diabetic Patients Who Are Poorly Controlled On Sulphonylurea Treatment", Diabetes Care, 24(8):1416-1421 (2001)
Larsen et al., "Systemic Administration of the Long-Acting GLP-1 Derivative NN2211 Induces Lasting and Reversible Weight Loss in Both Normal and Obese Rats", <i>Diabetes</i> , 50:2530-2539 (2001)
Le Bras et al., "Fibroblast Growth Factor 2 Promotes Pancreatic Epithelial Cell Proliferation Via Functional Fibroblast Growth Factor Receptors During Embryonic Life", <i>Diabetes</i> 47:1236-1242 (1998)
Lima-Leite et al., "Synthesis and Biological Activities of the Human Gastrin analogs", Braz. J. Med. Biol. Res., 29:1253-1263 (1996)
Lingohr et al., "Activation of IRS-2-Mediated Signal Transduction by IGF-1, but Not TGF- Alpha or EGF, Augments Pancreatic Beta-Cell Proliferation", Diabetes, 51:966-976 (2002)
Logothetopoulos et al., in Handbook of Physiology (Am. Physiol. Soc. Washington, DC), Section 7,

Page 5 of 8 Attorney Docket No.: 24492-011 NATL

	C67	Lu et al., "Keratinocyte growth factor ameliorates streptozotocin-induced, moderate diabetes in rats",
		Diabetes, Abstract 1030, 48[s1], A236 (1999)
	C68	Marchese et al., "Human Keratinocyte Growth Factor Activity on Proliferation and Differentiation of
		Human Keratinocytes: Differentiation Response Distinguishes KGF From EGF Family", J. Cell.
		Physiol., 144: 326-332 (1990)
	C69	Messer, "Vasopressin and Oxytocin", web document updated 04/03/2000,
i		http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm, 5 pages.
	C70	Morales et al., Preserved GLP-I Effects on Glycogen Synthase a Activity and Glucose Metabolism in Isolated Hepatocytes and Skeletal Muscle From Diabetic Rats ³⁷ , Diabetes, 46:1264-1269 (1997)
	C71	Movassat et al., "Exendin-4 upregulates expression of PDX-1 and hastens differentiation and
		maturation of human fetal pancreatic β cells", Diabetes, Abstract 1416-P, page A341 (2001)
	C72	Munoz-Acedo et al, "Pancreatic changes in somatostatin content and receptor/effector system after
		intrapancreatic injection of 5,7-dihydroxytryptamine", J. Endocrinol., 145(2):227-234 (1995)
	C73	Nakano et al., "Hepatocyte growth factor is essential for amelioration of hyperglycemia in
- 1		streptozotocin-induced diabetic mice receiving a marginal mass of intrahepatic islet grafts",
		Transplantation, 69(2):214-221 (2000)
1	C74	Nathan et al., "Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic
		Subjects", Diabetes Care, 15(2):270-276 (1992)
	C75	Nauck et al., "Preserved Incretin Activity of Glucagon-like Peptide 1 [7-36 Amide] but Not of
- 1		Synthetic Human Gastric Inhibitory Polypeptide in Patients with Type-2 Diabetes Mellitus," J. Clin.
		Invest., 91:301-307 (1993)
- 1	C76	Nauck et al., "Additive Insulinopropic Effects of Exogenous Synthetic Human Gastric Inhibitory
1		Polypeptide and Glucagon-Like Peptide-1-(7-36) Amide Infused at Near-Physiological Insulinotropic
	C77	Hormone and glucose Concentrations", J. Clin. Endo. and Metab., 76(4):912-917 (1993) Nielsen J.H., "Effects of Growth Hormone, Prolactin, and Placental Lactogen on Insulin Content and
	Cii	Release, and Deoxyribonucleic Acid Synthesis in Cultured Pancreatic Islets", Endocrinology,
		110:600-606 (1982)
	C78	Nielsen et al., "The Role of Growth Hormone and Prolactin in Beta Cell Growth and Regeneration",
		Adv. Exp. Med. Biol., 321:9-17 (1992)
	C79	Nielsen et al., "Beta Cell Proliferation and Growth Factors", J. Mol. Med., 77:62-66 (1999)
	C80	Ohlsson et al., "The Method of Administration of Cholecystokinin Determines the Effects Evoked in
		the Pancreas", Pancreas, 23(1):94-101 (2001)
	C81	Ohlsson et al., "The Effect of Intermittent Injections of CCK-8S and the CCK-A Receptor Antagonist
		Devazepide on Cell Proliferation in Exocrine Rat Pancreas", Int. J. Pancreatol., 24:211-218 (1998)
	C82	Ohlsson et al., "Epidermal growth factor induces cell proliferation in mouse pancreas and salivary
		glands", Pancreas, 14(1):94-98 (1997)
	C83	Orskov et al, "Tissue and plasma concentrations of amidated and glycine-extended glucagon-like
		peptide I in humans", Diabetes, 43:535-539 (1994)
	C84	Parkes et al., "Insulinotropic Actions of Exendin-4 and Glucagon-Like Peptide-1 in Vivo and in
		Vitro", Metabolism, 50:583-589 (2001)
	C85	Pederson et al., "Effect of Cholecystokinin, Secretin, and Gastric Inhibitory Polypeptide on Insulin
		Release From the Isolated Perfused Rat Pancreas", Can. J. Physiol. Pharmacol., 57:1233-1237 (1979)
	C86	Perfetti et al., "Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic- Duodenum
		Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-
		Intolerant Rats", Endocrinology, 141:4600-4605 (2000)

Page 6 of 8 Attorney Docket No.: 24492-011 NATL

C87	Pierce et al., "Stimulation of All Epithelial Elements During Skin Regeneration by Keratinocyte Growth Factor", J. Exp. Med., 179:831-840 (1994)
C88	Projetto et al., "Glucose Utilization in Type 1 (Insulin-Dependent) Diabetes: Evidence for a Defect not Reversible by Acute Elevations of Insulin," <i>Diabetologia</i> , 25(4):331-335 (1983)
C89	Rehfeld et al., T"he Effect of Gastrin on Basal- and Glucose-Stimulated Insulin Secretion in Man", J. Clin. Invest., 52:1415-1426 (1973)
C90	Rehfeld, J.F., "The New Biology of Gastrointestinal Hormones", Physiol. Rev., 78:1087-1108 (1998)
C91	Rehfeld et al., "The Effect of Gastrin and Cholecystokinin on the Endocrine Pancreas", Frontiers of Hormone Research, 7:107-118 (1980)
C92	Ritzel et al., "Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance", Diabetes, 50:776-784 (2001)
C93	Rooman et al., "Effect of Vascular Endothelial Growth Factor on Growth and Differentiation of Pancreatic Ductal Epithelium", Lab. Invest., 76:225-232 (1997)
C94	Rooman et al., "Mitogenic effect of gastrin and expression of gastrin receptors in duct-like cells of rat pancreas", Gastroenterology, 121:940-949 (2001)
C95	Rooman et al., "Effects of gastrin on proliferating and differentiation in regenerating pancreas", Diabetologia, Abstract, page 106 (2000)
C96	Rooth et al., "Prevention of detrimental effect of cyclosporine A on vascular ingrowth of transplanted pancreatic islets with verapamil", <i>Diabetes</i> , 38(1):202-205 (1989)
C97	Rudinger, J. "Characeteristics of the amino acids as components of a peptide hormone sequence" Peptide Hormones, JA Parsons ed., pgs. 1-7 (1976)
C98	Sasaki et al., "Dietary Docosahexaenoic acid can alter the surface expression of CD4 and CD8 on T cells in peripheral blood", J. Agric. Food Chem., 48(4):1047-1049 (2000)
C99	Schmidt et al., "Glucagon-Like peptide-1 but not Glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets," <i>Diabetologia</i> , 28:704-707 (1985)
C100	Shapiro et al., "Combination Therapy With Low Dose Sirolimus and Tacrolimus Is Synergistic in Preventing Spontaneous and Recurrent Autoimmune Diabetes in Non-Obese Diabetic Mice", Diabetologia, 45:224-230 (2002)
C101	Shapiro et al., "Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus using a Glucocorticoid-Free Immunosuppressive Regimen", N. Eng. J. Med., 343(4):230-238 (2000)
C102	Sharma et al., "The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration", Diabetes, 48:507-513 (1999)
C103	SIGMA Big Gastrin I human, https://www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/G7264
C104	SIGMA Leu15-Gastrin 1 human, http://www.sigmaaldrich.com/catalog/search/ProductDetail/ProNo=G9145&Brand=Sigma
C105	SIGMA, Designing Custom Peptides, http://www.sigma-genosys.com/peptide design.asp (accessed 12/16/2004) 2 pages
C106	Sjoholm et al., 'TGF-Beta Stimulates Insulin Secretion and Blocks Mitogenic Response of Pancreatic Beta-Cells to Glucose", Am. J. Physiol., 260:C1046-C1051 (1991)
C107	Smilek et al., "A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis", Proc. Natl. Acad. Sci., USA, 88:9633-9637 (1991)
C108	Soon-Shiong et al., "Glucose-Insulin Kinetics of the Extravascular Bioartificial Pancreas", ASAIO J., 38:851-854 (1992)
C109	Soon-Shiong et al, "Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation" <i>Lancet</i> , 343:950-951 (1994)

Page 7 of 8 Attorney Docket No.: 24492-011 NATL

C110	Soon-Shiong et al, "Long-term reversal of diabetes by the injection of immunoprotected islets", <i>Proc. Natl. Acad. Sci. USA</i> , 90(12):5843-5847 (1993)
C111	Soon-Shiong et al, "Pancreas and islet-cell transplantation: Potential cure for diabetes", Transplantation, 87(8):133-134; 139-140 (1990)
C112	Soon-Shiong et al., "Successful reversal of spontaneous diabetes in dogs by Intraperitoneal microencapsulated islets", <i>Transplantation</i> , 54(5):769-774 (1992)
C113	Staiano-Coico et al., "Human Keratinocyte Growth Factor Effects in a Porcine Model of Epidermal Wound Healing", J. Exp. Med., 178:865-878 (1993)
C114	Todd et al., "Subcutaneous Glucagon-Like Peptide-1 Improves Postprandial Glycaemic Control Over a 3-Week Period in Patients With Early Type 2 Diabetes", Clin. Sci., 95:325-329 (1998)
C115	Tourrel et al., "Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the Beta-Cell Mass During the Prediabetic Period With Glucagon-Like Peptide-I or Exendin-4", <i>Diabetes</i> , 51:1443-1452 (2002)
C116	Tourrel et al., "Glucagon-Like Peptide-1 and Exendin-4 Stimulate Beta-Cell Neogenesis in Streptozotocin-Treated Newborn Rats Resulting in Persistently Improved Glucose Homeostasis at Adult Age", Diabetes, 50:1562-1570 (2016)
C117	Uttenthal et al., "Molecular forms of Glucagon-like peptide-1 in human pancreas and Glucagonomas," J. Clin. Endocrinol. Metab., 61:472-479 (1985)
C118	Vergelli et al., "Immunosuppresive activity of 13-cis-retinoic acid in rats: aspects of pharmacokinetics and pharmacodynamics", Immunopharmacology, 37:191-197 (1997)
C119	Villanueva-Penacarrillo et al., "Increased Glucagon-like Peptide 1 (7-36) Amide Binding in Adipose Fissue from Non-Insulin Dependent and Insulin-Dependent Diabetic Patients," <i>Diabetes Nutr. Metab.</i> , 7(3):143-148 (1994)
C120	Voet et al., Biochemistry, 2nd Edition, Section 9-3, "Abdominal Hemoglobins", pages 235-241 (1995)
C121	Wang et al., "Intraportal delivery of immunosuppression to intreaheptic islet allograft recipients", Transpl. Int., 8:268-272 (1995)
C122	Wang et al., "Glucagon-Like Peptide-I Can Reverse the Age-Related Decline in Glucose Tolerance in Rats", J. Clin. Invest., 99:2883-2889 (1997)
C123	Wang et al., "Glucagon-Like Peptide-1 Is a Physiological Incretin in Rat", J. Clin. Invest., 95:417-421 (1995)
C124	Wang et al., "Expression of gastrin and transforming growth factor-a during duct to islet cell differentiation in the pancreas of duct-ligated adult rats", Diabetologia, 40:887-893 (1997)
C125	Wettergren et al., "Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man," Digestive Diseases and Sciences, 38(4):665-673 (1993)
C126	Winer et al., "Autoimmune islet destruction in spontaneous type 1 diabetes is not β-cell exclusive", Nat. Med., 9(2):198-205 (2003)
C127	Wrighton et al., "Small peptides as potent mimetics of the protein hormone erythropoietin", Science, 273:458-463 (1996)
C128	Ye et al., "DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs", J. Controlled Rel., 64:155-166 (2000)
C129	Young et al., "Glucose-Lowering and Insulin-Sensitizing Actions of Exendin-4: Studies in Obese Diabetic (Ob/Ob, Db/Db) Mice, Diabetic Farty Zucker Rats, and Diabetic Rhesus Monkeys (Macaca Mulatata)", Diabetaes, 48:1026-1034 (1999).

Page 8 of 8 Attorney Docket No.: 24492-011 NATL

0400	Zhou et al., "Glucagon-Like Peptide 1 and Exendin-4 Convert Pancreatic AR42J Cells into
C130	Zhou et al., "Giucagon-Like Peptide 1 and Exendin-4 Convert Palicreatic AR423 Cens into
	Glucagon- and Insulin-Producing Cells", Diabetes, 48:2358-2366 (1999)

* By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A12-A23 and the U.S. Published Applications A24-A37 are not submitted.

Examiner Signature	/Elly Gerald Stoica/	Date Considered	04/03/2008	
-----------------------	----------------------	--------------------	------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 2251517v.1